2019 Jul 1;104(7):2953-2960
The tradeoff is that more receptors also means more side effects, especially nausea and (for retatrutide) unusual skin sensations
[4] [5] Germ-free and antibiotic studies first hinted at this: when the microbiome is altered, so is GLP-1 signaling and L-cell density
Additionally, GLP-1R expression in the nucleus ACBs may also contribute to this satiety function, more directly in the context of food-seeking motivated behaviors and reward signaling [56]
The demand for weight-loss medication also makes it a potential hotspot for criminal activity, with unregulated suppliers acting illegally and sometimes selling drugs that do not contain medication as labelled and put patients health at risk
This pattern is similar to other GLP-1based medications, where increasing the dose can improve results but also raises the chance of side effects